Stocks to watch at the open
- {{x.value}}
{{ twilioFailed ? 'SMS Code Failed to Send…' : 'Enter verification code' }}
{{ completedStep1 ? 'Authentication & Security' : content.trialHeading.replace('{0}', user.FirstName) }}
{{ content.upgradeHeading.replace('{0}', user.FirstName) }}
The email address you entered is registered with InvestSMART
Please login to continue
We have sent you an email with the details of your registration.
Looks you are already a member. Please enter your password to proceed
{{ upgradeCTAText }}
Updating information
Please wait ...
Your membership to InvestSMART Group recently failed to renew.
Please make sure your payment details are up to date to continue your membership.
Having trouble renewing?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
You've recently updated your payment details.
It may take a few minutes to update your subscription details, during this time you will not be able to view locked content.
If you are still having trouble viewing content after 10 minutes, try logging out of your account and logging back in.
Still having trouble viewing content?
Please contact Member Services on support@investsmart.com.au or 1300 880 160
Please click on the ACTIVATE button to activate your Intelligent Investor 15-day free trial
Please click on the ACTIVATE button to finalise your membership
Unsuccessful registration
Registration for this event is available only to Eureka Report members. View our membership page for more information.
Registration for this event is available only to Intelligent Investor members. View our membership page for more information.
- You are already registered for this event.
- This event is already full.
- Please select a quantity for at least one ticket.
- {{ i }}
Forgotten password
Please enter your email address below to request a new password
- Verify your email address by clicking on the link we sent to {{user.Email}}
- You now have free access, we look forward to helping you on your financial journey.
CSL
Competitor to CSL, Baxter International, has submitted an application to the European Medicines Agency to approve its Haemophilia B drug.
The threat for CSL is it will not be able to compete with new haemophilia therapies, losing market share and earnings along the way.
CSL closed at any all-time high yesterday, and earlier this week Credit Suisse raised its target price to $74.55 with an outperform outlook.
David Jones
Today David Jones reports its sales for the first quarter.
Statistics show August was a challenging month for retail, but conditions may have improved following the election early in September.
Total sales analyst estimates for the period for David Jones range from flat to an increase of over 2 per cent. The market is likely to have a bad reaction to negative figures, especially as the department store is still without a replacement for recently resigned chief executive Paul Zahra.
The analyst consensus for David Jones is negative, with the majority of views either a sell or underperform.
Newcrest Mining
Spot gold slipped 1.5 per cent to close at $US1,324.26. Inflation slowed in the eurozone more than forecast, encouraging losses in the precious metal. Falling inflation doesn’t bode well for the price of gold, and suggests further losses could be on the cards in the short term.
Newcrest’s September quarter production numbers were impressive, but continuing volatility in the gold price is creating cash flow uncertainty for the struggling miner.
Trading at $10.30, Newcrest is nearing yearly lows.
Call 1300 880 160
Start a chat
Schedule a call
